Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-Seq Analysis of p53 Knockdown validated Human SU. 86.86 Pancreatic Cancer cells

ABSTRACT: The purpose of this study is to understand the differential gene expression analysis in p53 knockdown human SU.86.86 pancreatic cancer cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE206943 | GEO | 2025/06/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-Seq Analysis of p53 Knockdown validated Human SU. 86.86 Pancreatic Cancer cells

Project description:RNA-Seq Analysis of p53 Knockdown validated Human SU. 86.86 Pancreatic Cancer cells

| PRJNA852804 | ENA

A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-Yap axis in pancreatic cancer

Project description:The p53 transcription factor is a critical barrier to pancreatic cancer progression. To unravel mechanisms of p53-mediated tumor suppression, we analyzed pancreatic cancer predisposition in mice expressing p53 transactivation domain (TAD) mutants. Surprisingly, we observed that p53 TAD2 mutant behaves as a “super-tumor suppressor”, with an enhanced capacity to suppress pancreatic cancer and to activate a subset of novel p53 target genes. One such gene, Ptpn14, is a direct p53-inducible gene encoding a negative regulator of the Yap oncoprotein. To determine the effects of p53 deficiency on Yap target gene expression in pre-malignant mouse pancreatic intraepithelial neoplasia (PanIN) lesions, we sorted the CD133-positive ductal epithelial cells that make up the PanINs and used these cells for RNA-sequencing analysis. This analysis revealed that a Yap signature is induced upon p53 deficiency, suggesting that p53 loss promotes the induction of a Yap transcriptional program.

2017-10-26 | GSE94566 | GEO

Gene expression in SU-DIPG20, SU-DIPG31, SU-DIPG35, and SU-DIPG-48 primary human tumor samples

Project description:Gene expression in SU-DIPG20, SU-DIPG31, SU-DIPG35, and SU-DIPG-48 primary samples was quantified to gain insight into diffuse glioma biology.

2023-01-29 | GSE223712 | GEO

Gene expression in SU-DIPG20, SU-DIPG31, SU-DIPG35, and SU-DIPG-48 primary human tumor samples

Project description:Gene expression in SU-DIPG20, SU-DIPG31, SU-DIPG35, and SU-DIPG-48 primary human tumor samples

| PRJNA927324 | ENA

Pancreatic Cancer HPAF/CD18 cells: Ecd knockdown vs Scrambled

Project description:Purpose: To study the expression and function of a novel cell cycle regulatory protein, human ecdysoneless (Ecd), during pancreatic cancer (PC) pathogenesis. Experimental Design: Immunohistochemical expression profiling of Ecd was done in non-neoplastic normal pancreatic tissues and pancreatic ductal adenocarcinoma lesions (from tissue microarray and Rapid Autopsy program) as well as precancerous PanIN lesions and metastatic organs. To analyze the biological significance of Ecd in PC progression, Ecd was stably knocked down in PC cell line followed by in vitro and in vivo functional assays. Results: Normal pancreatic ducts show very weak to no Ecd expression compared to significant positive expression in PC tissues (mean±SE composite score: 0.3±0.2 and 3.8±0.2 respectively, p<0.0001) as well as in PanIN precursor lesions with a progressive increase in Ecd expression with increasing dysplasia (PanIN-1 to PanIN-3). Analysis of matched primary tumors and metastases from PC patients revealed that Ecd is highly expressed in both primary pancreatic tumor and in distant metastatic sites. Further, knockdown of Ecd suppressed cell proliferation in vitro and tumorigenicity of PC cells in mice orthotopic tumors. Microarray study revealed that Ecd regulates expression of glucose transporter GLUT4 in PC cells and was subsequently shown to modulate glucose uptake, lactate production and ATP generation by PC cells. Finally, knockdown of Ecd also reduced level of pAkt, key signaling molecule known to regulate aerobic glycolysis in cancer cells. Conclusion: Ecd is a novel tumor promoting factor that is differentially expressed in pancreatic cancer and potentially regulates glucose metabolism within cancer cells. Two-condition experiment, Ecd knockdown vs Scrambled cells. Biological replicates: 3 Ecd knockdownl, 3 Scrambled, independently grown and harvested. One replicate per array

2012-08-09 | E-GEOD-39988 | biostudies-arrayexpress

Molecular characterization of immortalization of human MSCs by a combination of p53 knockdown and TERT overexpression

Project description:Gene expression profile of p53 knockdown MSCs or p53 knockdown+TERT MSCs was compared with that of control MSCs. Our data show p53 knockdown prolongs the lifespan of MSCs, and a combination of p53 knockdown and TERT overexpression is sufficient to immortalize MSCs. The results provide important information about the molecular basis underlying p53 knockdown in MSCs and immortalization-related genes of MSCs. Total RNA obtained from p53 knockdown MSCs or p53 knockdown+TERT MSCs from three patients were compared with control MSCs.

2011-04-13 | E-GEOD-28546 | biostudies-arrayexpress

Molecular characterization of immortalization of human MSCs by a combination of p53 knockdown and TERT overexpression

2011-04-13 | GSE28546 | GEO

MCT4 knockdown in pancreatic cancer cells

Project description:Gene expression levels were determined with control or MCT4 knockdown pancreatic cancer cells.

2014-12-17 | GSE63231 | GEO

The role of p53 in pancreatic cancer suppression

Project description:The role of p53 in pancreatic cancer suppression

| PRJNA932333 | ENA

RNA-Seq Analysis of p53 Knockdown and Knock out Human Cancer cells

Project description:The purpose of this study is to understand the role of p53 protein in p53 mutant and wild type cancer cells

2026-04-30 | GSE175617 | GEO